Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Anemia Associated with Chronic Renal Failure Condition: Chronic renal failure on dialysis, not currently on Erythropoiesis-Stimulating Agent therapy |
Dose: Intravenous or Subcutaneous Injection – 0.6 mcg/kg Frequency: every 2 weeks initially Note: Initiate treatment when hemoglobin level less than 10 g/dL. If hemoglobin level approaches or exceeds 11 g/dL, reduce or interrupt dose. Do not increase dose more frequently than every 4 weeks; decreases in dose can occur more frequently; avoid frequent dose adjustments. If hemoglobin rises rapidly (e.g., greater than 1 g/dL in any 2-week period), reduce dose by 25% or more as needed. For patients who do not respond adequately, if hemoglobin has not increased by greater than 1 g/dL after 4 weeks of therapy, increase dose by 25%. |
|
Indication: Anemia Associated with Chronic Renal Failure Condition: Chronic renal failure on dialysis, hemoglobin stabilized |
Dose: Intravenous or Subcutaneous Injection – Twice the every-two-week dose Frequency: once monthly Note: Titrate as necessary. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Child |
Dose: Safety & efficacy not established Note: Safety and efficacy have not been established in children |
Administration
- IV route recommended for hemodialysis
- Inject in abdomen, arm or thigh
Side Effect
- Hypertension (13%)
- Diarrhea (11%)
- Nasopharyngitis (11%)
- Headache (9%)
- Upper respiratory tract infection (URTI) (9%)
- Cough (6%)
- Hypotension (5%)
- Urinary Tract Infection (UTI) (5%)
- Procedural arteriovenous fistula thrombosis (5%)
- Coronary artery disease
- Anemia
- Septic shock
- Serious cardiovascular and thromboembolic events
- Seizures
- Immunogenicity related PRCA
- Increased mortality and/or tumor progression in cancer patients
- Increased mortality
- Concomitant termination of other CRF therapy
- Stevens-Johnson syndrome
- Toxic epidermal necrolysis
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
ACE Inhibitors (Captopril, Enalapril, Lisinopril, Ramipril, Benazepril, Fosinopril, Quinapril, Perindopril), angiotensin-II receptor antagonists
|
Antagonises the hypotensive effects and increases risk of hyperkalaemia
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Uncontrolled Hypertension
|
Risk of hypertensive crisis
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store in a refrigerator 2°C–8°C. Keep the vial/cartridge/pre-filled syringe in the outer carton, in order to protect from light
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.